Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases
Quazim A. Alayo, Aava Khatiwada, Anish Patel, Maria Zulfiqar, Anas Gremida, Alexandra Gutierrez, Richard P. Rood, Matthew A. Ciorba, George P. Christophi, Parakkal Deepak
Abstract
Despite the availability of a range of novel therapeutics to treat patients with moderate to severe inflamamtory bowel disease (IBD), a significant proportion are either primary or secondary nonresponders to these therapeutics. Recently, there have been a number of reports demonstrating that dual biologic therapy (DBT) combining mechanistically different biologics may be a potential therapeutic option in this patient population.1–6 There is, however, a paucity of data on the effectiveness and safety of DBT in general, and particularly combining tofacitinib, an oral, small-molecule Janus Kinase (JAK) inhibitor, with a biologic in patients with refractory IBD. We conducted a retrospective...